Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study

This paper is a clinical phase 1 dose escalation study examining the long-term outcomes of using somatostatin receptor targetted therapy with [90Y-DOTA]-TOC in patients with progressive neuroendocrine tumours. The authors examined the survival and both short-term and long-term toxicities of a number of different dosage regimes. They found there was increasing toxicity with higher dosage levels, with longer-term outcomes suggesting that fractionated [90Y-DOTA]-TOC treatment could be used to increase survival and decrease renal toxicity.

Marincek, N et al. 2013. Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study. Journal of Translational Medicine, 11:17.

This article is open access and available to read here.